autologous stem cell therapies
-
Coeptis Therapeutics’ Dave Mehalick on Making Cell Therapy Universally Accessible
April 30, 2024 — In a recent interview with InvestorNews, Dave Mehalick, Chairman, President, and CEO of Coeptis…
-
Dave Mehalick from Coeptis Therapeutics to Host InvestorTalk (04.25.2024)
InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for Thursday, April 25th at 9 AM EST, featuring…
-
Coeptis Therapeutics’ Dave Mehalick on the disruptive potential of SNAP-CAR technology for autoimmune diseases
In an insightful interview with Tracy Weslosky, Dave Mehalick, Chairman, President, and CEO of Coeptis Therapeutics Holdings, Inc.…
-
Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for…
-
Thomas Smeenk of Hemostemix talks about market reaction to successful litigation settlement
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and…
